PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells

Oncogene

Volumn 36, Issue 2, 2017, Pages 263-274

  Banasavadi Siddegowda, Y K ^a   Russell, L ^a   Frair, E ^a   Karkhanis, V A ^a   Relation, T ^a   Yoo, J Y ^a   Zhang, J ^b   Sif, S ^c   Imitola, J ^a   Baiocchi, R ^a   Kaur, B ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Center for Biostatistics   (United States)

^c Qatar University ^*  (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN E; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN ARGININE METHYLTRANSFERASE ENZYME 5; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; PRMT5 PROTEIN, HUMAN; PROTEIN ARGININE METHYLTRANSFERASE; PTEN PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL AGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTRACRANIAL TUMOR; LUCIFERASE ASSAY; MOUSE; MTT ASSAY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STEM CELL CULTURE; STEM CELL SELF-RENEWAL; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL CYCLE; CELL SELF-RENEWAL; CYTOLOGY; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; BRAIN NEOPLASMS; CELL AGING; CELL CYCLE; CELL SELF RENEWAL; GLIOBLASTOMA; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PROTEIN-ARGININE N-METHYLTRANSFERASES; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84974686603     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.199     Document Type: Article

References (46)

1. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26: 756-784
2. Stupp R, Hegi ME, Mason WP, Van den Bent MJ, Taphoorn MJ, Janzer RC et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466
3. Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012; 38: 271-291
4. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010; 16: 2443-2449
5. Scoumanne A, Zhang J, Chen X. PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Res 2009; 37: 4965-4976
6. Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 2009; 16: 304-311
7. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S. Human SWI/SNFassociated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 2004; 24: 9630-9645
8. Yan F, Alinari L, Lustberg ME, Martin LK, Cordero-Nieves HM, Banasavadi- Siddegowda Y et al. Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res 2014; 74: 1752-1765
9. Han X, Li R, Zhang W, Yang X, Wheeler CG, Friedman GK et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J Neurooncol 2014; 118: 61-72
10. Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, Singer O et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012; 338: 1080-1084
11. Karberg S. Switching on epigenetic therapy. Cell 2009; 139: 1029-1031
12. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812
13. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403
14. Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S et al. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cells 2013; 31: 870-881
15. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330
16. Adams PD, Kaelin WG Jr. Transcriptional control by E2F. Semin Cancer Biol 1995; 6: 99-108
17. Qian Y, Luckey C, Horton L, Esser M, Templeton DJ. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol Cell Biol 1992; 12: 5363-5372
18. Stevaux O, Dyson NJ. A revised picture of the E2F transcriptional network and RB function. Curr Opin Cell Biol 2002; 14: 684-691
19. Dahiya A, Wong S, Gonzalo S, Gavin M, Dean DC. Linking the Rb and polycomb pathways. Mol Cell 2001; 8: 557-569
20. Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D. Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol 2001; 21: 6484-6494
21. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331-342
22. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-Type cyclins. Cell 1993; 73: 487-497
23. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993-1006
24. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512
25. Hengst L, Reed SI. Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998; 227: 25-41
26. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-Trisphosphate. J Biol Chem 1998; 273: 13375-13378
27. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39
28. Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science 2013; 341: 399-402
29. Goldstein S. Replicative senescence: the human fibroblast comes of age. Science 1990; 249: 1129-1133
30. Sherwood SW, Rush D, Ellsworth JL, Schimke RT. Defining cellular senescence in IMR-90 cells: a flow cytometric analysis. Proc Natl Acad Sci USA 1988; 85: 9086-9090
31. Cristofalo VJ, Phillips PD, Sorger T, Gerhard G. Alterations in the responsiveness of senescent cells to growth factors. J Gerontol 1989; 44: 55-62
32. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-9367
33. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196: 33-39
34. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828
35. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401
36. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760
37. Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11: 503-511
38. Wu CH, Van Riggelen J, Yetil A, Fan AC, Bachireddy P, Felsher DW. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci USA 2007; 104: 13028-13033
39. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464: 374-379
40. Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010; 120: 681-693
41. Tan W, Gu Z, Shen B, Jiang J, Meng Y, Da Z et al. PTEN/Akt-p27(kip1) signaling promote the BM-MSCs senescence and apoptosis in SLE patients. J Cell Biochem 2015; 116: 1583-1594
42. Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, Lee BL et al. PTEN status switches cell fate between premature senescence and apoptosis in glioma exposed to ionizing radiation. Cell Death Differ 2011; 18: 666-677
43. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91: 1922-1932
44. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947
45. McDowell KA, Riggins GJ, Gallia GL. Targeting the AKT pathway in glioblastoma. Curr Pharm Des 2011; 17: 2411-2420
46. Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008; 16: 1546-1555